Psoriatic Disease

Despite a low number of major adverse cardiovascular events overall, patients with psoriatic arthritis who newly start IL-12/23 or IL-17 inhibitors have a greater cardiovascular risk than those who begin TNF inhibitors, according to data.

Guselkumab 100 mg administered every 4 or 8 weeks produced “meaningful and sustained” improvements in fatigue through 1 year in patients with psoriatic arthritis, according to data published in Arthritis & Research & Therapy.

Both ustekinumab and TNF inhibitors demonstrate significant improvement in psoriatic arthritis disease activity, with similar positive results in minimal and low disease activity, and remission, after 6 months, according to data.

Guselkumab administered once every 4 or 8 weeks improved axial outcomes in patients with psoriatic arthritis who have sacroiliitis through week 52, according to data published in The Lancet Rheumatology.

Risankizumab is linked to significantly greater improvements in psoriatic arthritis signs and symptoms than placebo in patients with an inadequate response, or intolerance, to other drugs, according to a speaker at the EULAR 2021 Congress.

Fecal microbiota transplantation is safe in patients with psoriatic arthritis, according to data from the first preliminary, randomized trial of the procedure in immune-mediated arthritis.

Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those higher rates through 1 year, in patients with psoriatic arthritis, according to data published in Rheumatology.

Psoriasis and psoriatic arthritis remain medically disqualifying conditions for entrance into the U.S. military, and many treatments for psoriatic disease could inhibit those who are enlisted from continuing to serve.

Guselkumab is comparable to interleukin-17A and subcutaneous TNF inhibitors for efficacy, and demonstrated a better PASI response relative to other drugs, in patients with psoriatic arthritis, according to a meta-analysis published in Rheumatology.

The combined “derm-rheum” clinic offers a unique opportunity to streamline care and improve drug access for patients with psoriatic arthritis while enhancing cross-disciplinary education among dermatologists and rheumatologists, noted a speaker at a recent summit.